OTN’s Specialty Pharmacy, ivpcare, Selected to Dispense Newly Approved Tykerb® to Advanced Breast Cancer Patients

Oral Chemotherapy Immediately Available By Prescription for Home Delivery to Patients

South San Francisco, CA -- March 22, 2007 -- OTN, a leading physician services company and one of the largest distributors of products and services to the community physician market,  today announced that, effective immediately, patients with advanced breast cancer can obtain Tykerb® (lapatinib) by prescription through OTN’s national specialty pharmacy, ivpcare. 

The U.S. Food and Drug Administration approved Tykerb on March 13, 2007, for the treatment of advanced or metastatic breast cancer in combination with Xeloda® (capecitabine).  Tykerb is an oral treatment available to cancer patients only by prescription through a specialty pharmacy.

“ivpcare was selected to dispense this new breakthrough cancer treatment to patients based on our longstanding history of excellent customer service, reliability and full-service capabilities,” said Rebecca M. Shanahan, president of OTN Specialty Services, of which ivpcare is a division.  “Tykerb is just one of many cutting-edge therapies and oral chemotherapy medications that we distribute to patients with chronic conditions, including cancer.”

Physicians can call in prescriptions for Tykerb and Xeloda to ivpcare at 800-424-9002 or fax them to 800-874-9179.  Breast cancer patients can initiate an order at www.ivpcare.com/pharmacy effective immediately.  ivpcare will then contact the patient’s physician for the prescription.  For more information, including safety information, please visit http://www.tykerb.com.

In addition to 24-hour customer service, ivpcare offers guaranteed overnight delivery in carefully packaged containers to a patient’s home or physician’s office, reimbursement assistance, in-house benefits investigation experts, educational tools and supplies.  ivpcare also offers proactive refill notifications and drug therapy management programs.  Through these programs, ivpcare pharmacists and nurses stay in close contact with patients to help ensure they properly administer their drug therapy and adhere to their treatment plan.

OTN is an industry-leading oncology services company that provides oncology drugs, supportive care products and related supplies to more than 2,400 office-based oncology practices in the United States, comprising more than 4,000 physicians.  OTN was recognized as one of InformationWeek's top 500 companies in 2003 and 2004 and was honored with Frost & Sullivan's 2005 Customer Value Enhancement Award in recognition of its role in advancing cancer care in the community-based setting.  OTN continues to develop innovative technology solutions to help oncology practices improve practice efficiency, minimize costs and maximize revenues.  OTN is dedicated to helping community-based oncology practices extend and enhance the lives of people with cancer by offering the highest level of customer service and a knowledgeable support staff.  For more information, please visit http://www.myOTN.com.

ivpcare is the largest privately held national specialty pharmacy offering clinical services and distribution of pharmaceuticals developed for chronic therapeutic indications.  ivpcare provides comprehensive programs for patients, physicians, payors and pharmaceutical manufacturers for a growing number of disease states including hepatitis C, infertility, rheumatoid arthritis, multiple sclerosis, Crohn's disease and others.  Headquartered in Frisco, Texas, ivpcare has distribution facilities there, as well as in Torrance, Calif., St. Louis, Mo., and Wilmington, Mass.